In a phase II study of the long-acting GLP-1RA efpeglenatide (4 mg once weekly, 6 mg once weekly, 6 mg once every 2 weeks, and 8 mg once every 2 weeks), patients with obesity and without diabetes had statistically significant reductions in body weight compared with placebo after 20 weeks of treatment (differences in least squares means were 6.3 to 7.2 kg
larger meals more spread apart
"You have some very paternalistic employers out there that believe in the efficacy of these drugs
I know one of them has lost 100 pounds here and the other one has lost 50 (pounds). The semaglutide shortage has been going on for more than one year, according to Crannage, because Novo Nordisk, the manufacturer of Ozempic and Wegovy, has not been able to keep up with the demand
Due to these potential side effects, it is recommended to work under the supervision of a healthcare provider when getting treated with semaglutide, ensuring the benefits outweigh the risks for the patients, taking into account the medical history of the patient and potential drug interactions